Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on July 21, 2010, to announce its financial results for the second quarter of 2010. The report itself is brief, primarily serving as a cover for an attached press release (Exhibit 99.1) which contains the detailed financial and operational information. Investors should refer to this press release for specifics on the company's performance during the quarter.
Key Highlights
- 1Edwards Lifesciences filed an 8-K on July 21, 2010.
- 2The filing's primary purpose is to report financial results for the second quarter of 2010.
- 3The detailed results are provided in an attached press release, Exhibit 99.1.
- 4The report references the company's status as a Delaware corporation.
- 5Key financial figures and operational highlights for Q2 2010 are contained within the referenced press release.
- 6Thomas M. Abate, Corporate Vice President, Chief Financial Officer and Treasurer, signed the report.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Edwards Lifesciences Corporation's financial results for the second quarter of 2010, as per SEC regulations.
The detailed financial results, including specific revenue, profit, and other key metrics for the second quarter of 2010, are provided in the press release attached as Exhibit 99.1 to this 8-K filing.
This 8-K filing itself does not contain forward-looking statements or guidance. Such information would typically be found within the press release (Exhibit 99.1) or in subsequent filings.
Thomas M. Abate is the Corporate Vice President, Chief Financial Officer, and Treasurer of Edwards Lifesciences Corporation. He is the authorized signatory for this 8-K filing.